Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-11-16
2009-12-08
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
Reexamination Certificate
active
07629171
ABSTRACT:
The present invention relates to genetically altered hybridomas, myelomas and B cells. The invention also relates to utilizing genetically altered hybridomas, myelomas and B cells in methods of making monoclonal antibodies. The present invention also provides populations of hybridomas and B cells that can be utilized to make a monoclonal antibody of interest.
REFERENCES:
patent: 4978625 (1990-12-01), Wagner et al.
patent: 5212072 (1993-05-01), Blalock et al.
patent: 5264341 (1993-11-01), Maciak
patent: 5464758 (1995-11-01), Gossen et al.
patent: 5627052 (1997-05-01), Schrader
patent: 7148040 (2006-12-01), Meagher et al.
patent: 19900635 (2000-07-01), None
Attwood T., Science 2000; 290:471-473.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Antczak D.F. “Monoclonal antibodies: technology and potential use”J Am Vet Med Assoc181, 1005-10, 1982.
Condon et al. “Aberrant trafficking of the B cell receptor Ig-alpha beta subunit in a B lymphoma cell line”J Immunol165, 1427-37, 2000.
Coursen et al. “Genomic instability and telomerase activity in human bronchial epithelial cells during immortalization by human papillomavirus-16 E6 and E7 genes”Exp Cell Res235, 245-53, 1997.
DeFranco et al. “Structure and Function of the B-Cell Antigen Receptor”Chem Immunol. 59:156-172, 1994.
Dickson et al. “Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics”Mol Cell Biol20(4):1436-47, 2000.
Edwards-Gilbert, G. and Milcarek, C. “The binding of a subunit of the general polyadenylation factor cleavage polyadenylation specificity factor CPSF) to polyadenylation sites changes during B cell development”Nucleic Acids Symposium Series33, 229-233, 1995.
Edwalds-Gilbert, G. and Milcarek, C. “Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner”Molecular and Cellular Biology15, 6420-6429, 1995.
Edwalds-Gilbert et al. “Alternative poly(A) site selection in complex transcription units: means to an end?”Nucleic Acids Res25, 2547-2561, 1997.
Flaspohler et al. “The 3′-untranslated region of membrane exon 2 from the gamma 2a immunoglobulin gene contributes to efficient transcription termination”Journal of Biological Chemistry270, 11903-11, 1995.
Flaspohler, J. A. and Milcarek. C. “Myelomas and lymphomas expressing the Igγ2a H chain gene have similar transcription termination regions”Journal of Immunology144, 2802-2810, 1990.
Flaswinkel and Reth, “Molecular cloning of the Ig-α subunit of the human B-cell antigen receptor complex.”Immunogenetics36:266-269, 1992.
Flaswinkel and Reth, Dual role of the tyrosine activation motif of the Ig-α protein during signal transduction via the B cell antigen receptor.The EMBO Journal13(1):83-89, 1994.
Fraser, C.M. and Venter, J.C. “Monoclonal antibodies to beta-adrenergic receptors: use in purification and molecular characterization of beta receptors”Proc Natl Acad Sci77, 7034-8, 1980.
Galli et al. “Relative position and strengths of poly(A) sites as well as transcription termination are critical to membrane vs secreted mu-chain expression during B-cell development”Genes&Dev1, 471-481, 1987.
Genovese et al. “Differential mRNA stabilities affect mRNA levels in mutant mouse myeloma cells”Somat Cell Mol Genet17, 69-81, 1991.
Genovese C. and Milcarek, C. “Increased half-life of mu immunoglobulin mRNA during mouse B cell development increases its abundancy”Mol Immunol27, 733-43, 1990.
Glennie, M.J. and Johnson, P.W. “Clinical trials of antibody therapy”Immunol Today21, 403-10, 2000.
Glennie, M.J. and van de Winkel, Jan G.J. “Renaissance of cancer therapeutic antibodies.”DDT8(11):503-510, 2003.
Gold and Matsuuchi, “Signal Transduction by the Antigen Receptors of B and T Lymphocytes”International Review of Cytology157:181-276, 1995.
Graziano and Fanger “FcγRI and FcγRII on Monocytes and Granulocytes are Cytotoxic Trigger Molecules for Tumor Cells”J. of Immun. 139: 3536-3541, 1987.
Green, Larry L. “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.”J. Immuno. Methods231:11-23, 1999.
Greenberg et al. “Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation”Oncogene18, 1219-26, 1999.
Greene et al. “Monoclonal antibodies to human estrogen receptor”Proc Natl Acad SciU S A 77, 5115-9, 1980.
Guise et al. “Alternative expression of secreted and membrane forms of immunoglobulin μ-chain is regulated by transcriptional termination in stable plasmacytoma transfectants”Journal of Immunology140, 3988-3994, 1988.
Hall, B. L. and Milcarek, C. “Sequence and polyadenylation site determination of murine immunoglobulin gamma 2a membrane 3′ untranslated region”Mol Immunol26, 819-826, 1989.
Hashimoto et al. “Alternative splicing ofCD79a(Ig-alpha/mb-1) andCD79b(Ig-beta/B29) RNA transcripts in human B cells”Mol Immunol32, 651-9, 1995.
Hattori et al. “The DNA sequence of human chromosome 21. The chromosome 21 mapping and sequencing consortium” Nature 405, 311-9, 2000.
Hombach et al. “Identification of the genes encoding the IgM-alpha and Ig-beta components of the IgM antigen receptor complex by amino-terminal sequencing”Eur J Immunol20, 2795-9, 1990.
Hombach et al. “Molecular components of the B-cell antigen receptor complex of the IgM class”Nature343, 760-2, 1990.
Hurwitz et al. “CHgene rearrangements in IgM-bearing B cells and in the normal splenic DNA component of hybridomas making different isotypes of antibody”Cell22, 349-59, 1980.
Kanavaros et al. “Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas”Am J Pathol146, 735-41, 1995.
Kandasamy et al. “The late pollen specific actins in angiosperms”Plant J18, 681-691, 1999.
Kelly, D. E., and Perry, R. P. “Transcriptional and post-transcriptional control of Ig mRNA production during B lymphocyte development”Nucleic Acids Research14, 5431-5441, 1986.
Kim et al. “Immortalization of human embryonic fibroblasts by overexpression of c-myc and simian virus 40 large T antigen”Exp Mol Med33, 293-8, 2001.
Kim et al. “Differential signaling through the Ig-α and Ig-β components of the B cell antigen receptor”Mol. Immunol.23: 911-916, 1993.
Kiyono et al. “Both Rb/p16INK4ainactivation and telomerase activity are required to immortalize human epithelial cells”Nature396, 84-8, 1998.
Kobrin, B. J. et al. Sequences near the 3′ secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cellsMolecular and Cellular Biology 6, 1687-1697, 1986.
Kohler, G., and Milstein, C. “Continuous cultures of fused cells secreting antibody of predefined specificity”Nature256, 495, 1975.
Kohler and Milstein. “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.”Eur. J. Immunol. 6:495-497. (1975).
Kraus et al. “Ig-α Cytoplasmic Truncation Renders Immature B Cell More Sensitive to Antigen Contact,”Immunity11:537-545, 1999.
Laird et al. “50 million years of chordate evolution: Seeking the origins of adaptive immunity.”PNAS97(13):6924-6926, 2000.
Lassman, C. R., and Milcarek, C. “Regulated expression of the mouse γ2b Ig H chain gene is influenced by polyA site order and
Laterza Vince
Meagher Richard B.
Ballard Spahr LLP
Ouspenski Ilia
University of Georgia Research Foundation Inc.
LandOfFree
Genetically altered hybridomas, myelomas and B cells that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically altered hybridomas, myelomas and B cells that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically altered hybridomas, myelomas and B cells that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087781